Abbott Historical Income Statement

ABT Stock

USD 107.58 3.31 3.17%

Historical analysis of Abbott Laboratories income statement accounts such as Interest Expense of 605.1 M, Selling General Administrative of 6.2 B or Total Revenue of 22.2 B can show how well Abbott Laboratories performed in making a profits. Evaluating Abbott Laboratories income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Abbott Laboratories's future profits or losses.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Abbott Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Abbott Laboratories is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.

About Abbott Income Statement Analysis

Abbott Laboratories Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Abbott Laboratories shareholders. The income statement also shows Abbott investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Abbott Laboratories Income Statement Chart

At this time, Abbott Laboratories' Depreciation And Amortization is comparatively stable compared to the past year. EBITDA is likely to gain to about 11.1 B in 2024, whereas Total Revenue is likely to drop slightly above 22.2 B in 2024.

Selling General Administrative Gross Profit Other Operating Expenses

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Abbott Laboratories minus its cost of goods sold. It is profit before Abbott Laboratories operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Abbott Laboratories. It is also known as Abbott Laboratories overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Abbott Laboratories' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Abbott Laboratories current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.At this time, Abbott Laboratories' Depreciation And Amortization is comparatively stable compared to the past year. EBITDA is likely to gain to about 11.1 B in 2024, whereas Total Revenue is likely to drop slightly above 22.2 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	24.5B	24.5B	22.1B	12.5B
Total Revenue	43.1B	43.7B	40.1B	22.2B

Gross Profit Total Revenue

Abbott Laboratories income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Minority Interest	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Discontinued Operations	Tax Provision	Interest Income	Extraordinary Items	Net Interest Income
Depreciation And Amortization		0.81	0.73	0.75	0.76	0.75	0.66	0.6	0.86	0.72	0.75	0.68	0.08	0.56	0.3	0.78	0.47	-0.48	0.44	0.53	-0.03	-0.54	0.33	0.49	-0.43	-0.06
Interest Expense	0.81		0.65	0.61	0.61	0.65	0.37	0.41	0.61	0.6	0.69	0.36	0.13	0.18	0.44	0.57	0.63	-0.42	0.02	0.32	-0.01	-0.66	0.41	0.37	-0.75	-0.54
Selling General Administrative	0.73	0.65		0.96	0.97	0.98	0.8	0.7	0.65	0.94	0.99	0.77	-0.17	0.72	0.29	0.84	0.26	-0.76	0.29	0.5	-0.34	-0.31	0.23	0.36	-0.28	-0.21
Total Revenue	0.75	0.61	0.96		0.99	0.99	0.91	0.85	0.78	0.99	0.97	0.9	-0.17	0.83	0.35	0.79	0.37	-0.64	0.47	0.38	-0.28	-0.41	0.3	0.56	-0.34	-0.14
Gross Profit	0.76	0.61	0.97	0.99		0.98	0.91	0.82	0.76	0.97	0.97	0.89	-0.23	0.83	0.3	0.83	0.32	-0.65	0.48	0.4	-0.32	-0.38	0.25	0.5	-0.29	-0.14
Other Operating Expenses	0.75	0.65	0.98	0.99	0.98		0.85	0.81	0.74	0.99	0.99	0.85	-0.1	0.77	0.39	0.77	0.39	-0.68	0.38	0.4	-0.24	-0.42	0.33	0.53	-0.39	-0.22
Operating Income	0.66	0.37	0.8	0.91	0.91	0.85		0.89	0.81	0.88	0.8	0.96	-0.37	0.94	0.18	0.73	0.27	-0.42	0.73	0.25	-0.36	-0.33	0.17	0.59	-0.14	0.15
Ebit	0.6	0.41	0.7	0.85	0.82	0.81	0.89		0.87	0.88	0.72	0.94	-0.08	0.87	0.43	0.45	0.54	-0.26	0.64	-0.02	-0.07	-0.43	0.39	0.78	-0.41	-0.02
Ebitda	0.86	0.61	0.65	0.78	0.76	0.74	0.81	0.87		0.79	0.67	0.86	0.04	0.76	0.41	0.56	0.63	-0.33	0.6	0.22	-0.02	-0.53	0.42	0.75	-0.48	0.06
Cost Of Revenue	0.72	0.6	0.94	0.99	0.97	0.99	0.88	0.88	0.79		0.95	0.9	-0.08	0.81	0.43	0.7	0.44	-0.62	0.44	0.34	-0.2	-0.45	0.37	0.63	-0.41	-0.15
Total Operating Expenses	0.75	0.69	0.99	0.97	0.97	0.99	0.8	0.72	0.67	0.95		0.78	-0.12	0.7	0.34	0.82	0.33	-0.72	0.31	0.46	-0.28	-0.38	0.27	0.42	-0.36	-0.28
Income Before Tax	0.68	0.36	0.77	0.9	0.89	0.85	0.96	0.94	0.86	0.9	0.78		-0.12	0.96	0.34	0.66	0.34	-0.39	0.75	0.24	-0.12	-0.31	0.33	0.68	-0.2	0.12
Total Other Income Expense Net	0.08	0.13	-0.17	-0.17	-0.23	-0.1	-0.37	-0.08	0.04	-0.08	-0.12	-0.12		-0.23	0.6	-0.25	0.25	0.08	-0.21	0.06	0.88	0.0	0.63	0.12	-0.34	-0.26
Net Income	0.56	0.18	0.72	0.83	0.83	0.77	0.94	0.87	0.76	0.81	0.7	0.96	-0.23		0.14	0.62	0.22	-0.4	0.74	0.24	-0.23	-0.08	0.11	0.57	0.01	0.27
Income Tax Expense	0.3	0.44	0.29	0.35	0.3	0.39	0.18	0.43	0.41	0.43	0.34	0.34	0.6	0.14		0.09	0.51	-0.16	-0.02	-0.01	0.48	-0.33	0.94	0.44	-0.68	-0.4
Research Development	0.78	0.57	0.84	0.79	0.83	0.77	0.73	0.45	0.56	0.7	0.82	0.66	-0.25	0.62	0.09		-0.03	-0.61	0.46	0.68	-0.32	-0.22	0.12	0.15	-0.01	0.01
Minority Interest	0.47	0.63	0.26	0.37	0.32	0.39	0.27	0.54	0.63	0.44	0.33	0.34	0.25	0.22	0.51	-0.03		-0.11	0.06	-0.11	0.18	-0.57	0.41	0.72	-0.88	-0.33
Selling And Marketing Expenses	-0.48	-0.42	-0.76	-0.64	-0.65	-0.68	-0.42	-0.26	-0.33	-0.62	-0.72	-0.39	0.08	-0.4	-0.16	-0.61	-0.11		0.17	-0.73	0.45	0.03	-0.03	-0.06	0.1	0.09
Net Income From Continuing Ops	0.44	0.02	0.29	0.47	0.48	0.38	0.73	0.64	0.6	0.44	0.31	0.75	-0.21	0.74	-0.02	0.46	0.06	0.17		0.06	0.07	-0.22	0.08	0.52	0.11	0.35
Non Recurring	0.53	0.32	0.5	0.38	0.4	0.4	0.25	-0.02	0.22	0.34	0.46	0.24	0.06	0.24	-0.01	0.68	-0.11	-0.73	0.06		-0.16	0.01	-0.03	-0.07	0.13	0.19
Non Operating Income Net Other	-0.03	-0.01	-0.34	-0.28	-0.32	-0.24	-0.36	-0.07	-0.02	-0.2	-0.28	-0.12	0.88	-0.23	0.48	-0.32	0.18	0.45	0.07	-0.16		-0.06	0.55	0.17	-0.27	-0.25
Discontinued Operations	-0.54	-0.66	-0.31	-0.41	-0.38	-0.42	-0.33	-0.43	-0.53	-0.45	-0.38	-0.31	0.0	-0.08	-0.33	-0.22	-0.57	0.03	-0.22	0.01	-0.06		-0.32	-0.57	0.7	0.35
Tax Provision	0.33	0.41	0.23	0.3	0.25	0.33	0.17	0.39	0.42	0.37	0.27	0.33	0.63	0.11	0.94	0.12	0.41	-0.03	0.08	-0.03	0.55	-0.32		0.39	-0.61	-0.33
Interest Income	0.49	0.37	0.36	0.56	0.5	0.53	0.59	0.78	0.75	0.63	0.42	0.68	0.12	0.57	0.44	0.15	0.72	-0.06	0.52	-0.07	0.17	-0.57	0.39		-0.58	-0.04
Extraordinary Items	-0.43	-0.75	-0.28	-0.34	-0.29	-0.39	-0.14	-0.41	-0.48	-0.41	-0.36	-0.2	-0.34	0.01	-0.68	-0.01	-0.88	0.1	0.11	0.13	-0.27	0.7	-0.61	-0.58		0.62
Net Interest Income	-0.06	-0.54	-0.21	-0.14	-0.14	-0.22	0.15	-0.02	0.06	-0.15	-0.28	0.12	-0.26	0.27	-0.4	0.01	-0.33	0.09	0.35	0.19	-0.25	0.35	-0.33	-0.04	0.62

Click cells to compare fundamentals

Abbott Laboratories Account Relationship Matchups

Abbott Laboratories income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	2.1B	2.2B	2.3B	2.3B	3.2B	3.4B
Interest Expense	576M	500M	490M	375M	637M	605.2M
Selling General Administrative	9.8B	9.7B	11.3B	11.0B	11.2B	6.2B
Total Revenue	31.9B	34.6B	43.1B	43.7B	40.1B	22.2B
Gross Profit	18.7B	19.6B	24.5B	24.5B	22.1B	12.5B
Other Operating Expenses	27.4B	29.3B	34.7B	35.3B	33.6B	18.2B
Operating Income	4.5B	5.4B	8.4B	8.4B	6.5B	3.8B
Ebit	4.5B	5.4B	8.4B	8.4B	7.3B	3.7B
Ebitda	6.7B	7.6B	10.7B	10.7B	10.6B	11.1B
Cost Of Revenue	13.2B	15.0B	18.5B	19.1B	18.0B	9.6B
Total Operating Expenses	14.1B	14.2B	16.1B	16.1B	15.7B	8.6B
Income Before Tax	4.1B	5.0B	8.2B	8.3B	6.7B	3.8B
Total Other Income Expense Net	(56M)	(455M)	(389M)	(214M)	438M	459.9M
Net Income	3.7B	4.5B	7.1B	6.9B	5.7B	3.1B
Income Tax Expense	390M	497M	1.1B	1.4B	941M	792.1M
Research Development	2.4B	2.4B	2.7B	2.9B	2.7B	2.3B
Net Income Applicable To Common Shares	3.7B	4.5B	7.1B	6.9B	8.0B	8.4B
Minority Interest	201M	198M	213M	219M	251.9M	264.4M
Net Income From Continuing Ops	3.7B	4.5B	7.1B	6.9B	5.2B	4.3B
Non Operating Income Net Other	215M	157M	319M	502M	577.3M	606.2M
Tax Provision	390M	497M	1.1B	1.4B	1.0B	949.8M
Interest Income	94M	492M	491M	377M	384M	269.0M
Net Interest Income	(576M)	(500M)	(490M)	(375M)	(248M)	(260.4M)
Reconciled Depreciation	3.0B	3.3B	2.0B	2.0B	3.2B	2.3B

Pair Trading with Abbott Laboratories

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abbott Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abbott Laboratories will appreciate offsetting losses from the drop in the long position's value.

Moving together with Abbott Stock

0.77	VEEV	Veeva Systems Class	Pair Corr
0.79	CVS	CVS Health Corp Aggressive Push	Pair Corr

Moving against Abbott Stock

0.81	PDEX	Pro Dex	Pair Corr
0.74	HAE	Haemonetics	Pair Corr
0.61	LMAT	LeMaitre Vascular	Pair Corr
0.52	GH	Guardant Health	Pair Corr
0.37	ATRI	ATRION	Pair Corr

The ability to find closely correlated positions to Abbott Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abbott Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abbott Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abbott Laboratories to buy it.

The correlation of Abbott Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abbott Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abbott Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Abbott Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Abbott Stock Analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Abbott Historical Income Statement

About Abbott Income Statement Analysis

Abbott Laboratories Income Statement Chart

Gross Profit

Other Operating Expenses

Abbott Laboratories income statement Correlations

Abbott Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Abbott Laboratories income statement Accounts

Pair Trading with Abbott Laboratories

Moving together with Abbott Stock

Moving against Abbott Stock

Additional Tools for Abbott Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 0.99	Selling General Administrative
Gross Profit	+ 0.99	Total Revenue
Other Operating Expenses	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Other Operating Expenses
Total Operating Expenses	+ 0.99	Other Operating Expenses

Extraordinary Items	- 0.88	Minority Interest
Selling And Marketing Expenses	- 0.76	Selling General Administrative
Extraordinary Items	- 0.75	Interest Expense
Non Recurring	- 0.73	Selling And Marketing Expenses
Selling And Marketing Expenses	- 0.72	Total Operating Expenses
Extraordinary Items	- 0.68	Income Tax Expense